Novo Nordisk A/S Form 20-F Summary: Fiscal Year 2025
Business Context and Reporting Period
This Form 20-F covers the fiscal year ended December 31, 2025, for Novo Nordisk A/S, a global healthcare company headquartered in Denmark. The Company is a world leader in Obesity and Diabetes care, with a portfolio including GLP-1 receptor agonists (Ozempic, Wegovy, Rybelsus) and insulins. The reporting period reflects a year of significant organizational transformation, leadership changes, and strategic acquisitions.
Key Financial Metrics and Performance
While specific consolidated revenue and net profit figures for 2025 are incorporated by reference from the Annual Report 2025, the filing provides the following key data points:
- Product Sales:
- Ozempic: Global sales exceeded DKK 127 billion.
- Wegovy: Revenue grew 36% to DKK 79 billion.
- Total Obesity Care (Saxenda + Wegovy): Sales reached DKK 82,347 million (up from DKK 65,146 million in 2024).
- Victoza: Sales declined to DKK 3,020 million (from DKK 5,482 million in 2024) following patent expiration and generic entry.
- Capital Expenditures: Significant investments were made to expand manufacturing capacity. Realized spend as of December 31, 2025, included:
- Kalundborg, Denmark (API expansion): DKK 20.3 billion of DKK 22.3 billion expected.
- Kalundborg, Denmark (New API facility): DKK 23.1 billion of DKK 49.6 billion expected.
- Hillerød, Denmark (API expansion): DKK 10.7 billion of DKK 15.9 billion expected.
- Clayton, North Carolina, US: DKK 13.4 billion of DKK 27.0 billion expected.
- Acquisition: Acquired Akero Therapeutics Inc. for approximately USD 4.7 billion in cash plus a contingent value right (CVR) of up to USD 0.5 billion.
- Share Repurchases: Completed a DKK 20 billion repurchase program initiated in 2024, concluding in February 2025 with the purchase of 24,802,593 B shares.
- 340B Provision: As of December 31, 2025, provisions for 340B statutory discounts totaled USD 4.2 billion. Management expects to recognize this amount as revenue in Q1 2026 following a favorable HRSA ruling.
Material Changes vs. Prior Period
- Leadership Transition: Maziar Mike Doustdar succeeded Lars Fruergaard Jørgensen as CEO on August 7, 2025. The Board of Directors was also reconstituted in November 2025, with Lars Rebien Sørensen elected as Chair.
- Organizational Transformation: A company-wide transformation initiated in September 2025 resulted in the departure of approximately 9,000 employees globally, reducing the workforce by 10% to 69,505 by year-end.
- Market Dynamics: Despite continued growth, Novo Nordisk lost volume market share in the GLP-1 market for both obesity and diabetes in the US and ex-US markets due to increased competition. Wegovy lost its position as the leading anti-obesity medication by weekly prescriptions in the US early in 2025.
- Supply Chain: Periodic supply constraints for Ozempic persisted but improved throughout 2025 due to scaling of manufacturing capabilities.
- Patent Landscape: The compound patent for Victoza expired in major markets, leading to generic launches in 2024 and 2025. Semaglutide patents (Ozempic, Wegovy, Rybelsus) remain protected in the US until 2032.
Outlook, Risks, and Contingencies
Guidance and Outlook:
- Management expects continued pricing pressure in the US Obesity and Diabetes Care segment in 2026 due to rebates, payer consolidation, and competition.
- Revenue recognition of USD 4.2 billion related to the 340B Drug Pricing Program is expected in Q1 2026.
- Capital expenditures for 2026 are expected to be financed by cash flow from operating activities.
- Cybersecurity: Reliance on complex IT systems exposes the Company to potential breaches, though no material losses were reported in 2025.
- Climate Change: Production facilities in the US (North Carolina, Indiana) and other regions face risks from extreme weather events. Scope 3 decarbonization efforts are ongoing but have delayed effects.
- Regulatory and Pricing: The Inflation Reduction Act negotiations for Medicare Part D prices (effective 2027) and ongoing legal challenges regarding the 340B Drug Pricing Program pose financial uncertainties.
- Intellectual Property: The Company faces ongoing litigation and Paragraph IV certifications from generic manufacturers for key products like Ozempic and Wegovy.
- Compounding: Illicit compounding of GLP-1 products continues in the US despite the resolution of drug shortages, impacting market share.
Investor Verification Checklist
- 340B Revenue Recognition: Verify the timing and accounting treatment of the USD 4.2 billion revenue reversal expected in Q1 2026.
- Market Share Trends: Monitor the impact of competitor launches on Ozempic and Wegovy prescription volumes in the US market.
- Manufacturing Capacity: Track the operational readiness of major expansion projects in Kalundborg, Denmark, and Clayton, North Carolina, scheduled for 2027–2029.
- Patent Litigation: Review outcomes of ongoing patent infringement lawsuits and IPR proceedings regarding semaglutide products.
- Cost Synergies: Assess the financial impact of the 9,000-person workforce reduction and organizational restructuring on operating margins.
- Iran Operations: Confirm continued compliance with US sanctions regarding limited pharmaceutical activities in Iran.